FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2026/01/101981 [Registered on: 23/01/2026] Trial Registered Prospectively
Last Modified On: 20/01/2026
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Homeopathy 
Study Design  Other 
Public Title of Study   Treatment of plaque psoriasis with iris versicolor and individualised homoeopathic medicine in age group of 20-60 years. 
Scientific Title of Study   Assessing the effectiveness of Iris Versicolor and Individualised Homoeopathic Medicines selected through kent’s repertory in the management of plaque psoriasis A comparative study 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  DR SHRUTI PATIL  
Designation  PG SCHOLAR  
Affiliation  Government homoeopathic medical College and hospital  
Address  Government homoeopathic medical College and hospital Dr Siddaiah Puranik Road Basaveshwara Nagar Bengaluru 560079,1st floor,room no.49

Bangalore
KARNATAKA
560079
India 
Phone  7892601790  
Fax    
Email  shrutipatilpatil99@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  DR MUNIR AHMED R 
Designation  PROFESSOR  
Affiliation  Government homoeopathic medical College and hospital  
Address  Government homoeopathic medical College and hospital Dr Siddaiah Puranik Road Basaveshwara Nagar Bengaluru 560079,1st floor,room no.49

Bangalore
KARNATAKA
560079
India 
Phone  7892601790  
Fax    
Email  repertorypg@gmail.com  
 
Details of Contact Person
Public Query
 
Name  DR SHRUTI PATIL  
Designation  PG SCHOLAR  
Affiliation  Government homoeopathic medical College and hospital  
Address  Government homoeopathic medical College and hospital Dr Siddaiah Puranik Road Basaveshwara Nagar Bengaluru 560079,1st floor,room no.49


KARNATAKA
560079
India 
Phone  7892601790  
Fax    
Email  shrutipatilpatil99@gmail.com  
 
Source of Monetary or Material Support  
Government homoeopathic medical College and hospital  
 
Primary Sponsor  
Name  DR Shruti patil  
Address  Government homoeopathic medical College and hospital Dr Siddaiah Puranik Road Basaveshwara Nagar Bengaluru Karnataka 560079 
Type of Sponsor  Other [Principle investigator ] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
DR Shruti Patil   Government homoeopathic medical College and hospital  Government homoeopathic medical College and hospital Dr Siddaiah Puranik Road Basaveshwara Nagar Bengaluru
Bangalore
KARNATAKA 
7892601790

shrutipatilpatil99@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Government homoeopathic medical College and hospital   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: L408||Other psoriasis,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Individualised homoeopathic medicine   To assess the effectiveness of Individualized Homoeopathic Medicine selected through Kent’s Repertory in management of plaque psoriasis. 
Intervention  Iris versicolor   To assess the effectiveness of Iris versicolor in management of plaque psoriasis. 
 
Inclusion Criteria  
Age From  20.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  Subjects who are willing to participate as volunteers and sign the written informed consent.
Subjects aged between 20-60 years .
Subjects newly diagnosed with plaque psoriasis.


 
 
ExclusionCriteria 
Details 
Subjects with secondary systemic complications of psoriasis like psoriatic arthropathy.
Subjects with other systemic illness like diabetes, hypertension.
Subjects with atopic dermatitis, seborrheic dermatitis, lichen planus , Tinea corporis .
Pregnant and lactating women .
 
 
Method of Generating Random Sequence    
Method of Concealment    
Blinding/Masking    
Primary Outcome  
Outcome  TimePoints 
Reduction in severity of plaque psoriasis, measured objectively using a validated clinical scale, Psoriasis Area and Severity Index (PASI)from baseline to more than 75% by the end of the treatment period.  6 months 
 
Secondary Outcome  
Outcome  TimePoints 
A reduction in the sign and symptoms of psoriasis , recurrence with the same or less intensity and PASI score with more than 50 to 75% from the baseline.  6months 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   03/02/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   Need for the study:
Psoriasis is a chronic, immune mediated, inflammatory and non contagious skin disorder and have bimodal age distribution peaking at 20-30 years and 50-60 years. Chronic plaque psoriasis is the most common presentation of psoriasis , accounting more than 90% of cases.Globally, the prevalence of psoriasis varies from 0.1% to 3%,with 100million cases as per new WHO report 2016.
The prevalence of psoriasis in India varies from 0.44% to 2.8%, with equal distribution across all regions.
One third of patients with Psoriasis have a positive family history, associated with human leukocyte antigen(HLA-cw6). Psoriasis is associated with serious health complications like arthritis, cardiovascular diseases, hypertension, diabetes. Besides this it also lead to psychological distress like low self-esteem, anxiety, depression, social embarrassment, and risk of suicidal thoughts which complicates effective disease management.
In the Organon of Medicine (6th edition, §187–190) ,it clearly emphasizes that external manifestations like skin diseases are a reflection of internal disorders and must be treated internally rather than through mere local applications. Kent’s Repertory follows deductive logic, moving from general to particular. According to Kent, mind is prior to the body.
The constituents in the rhizome of Iris versicolor contains starch, gum, tannin, volatile oil, approximately 25% acrid resinous matter, isophthalic acid, and traces of salicylic acid. The resinous fraction also includes phenolic glycosides, which are believed to stimulate the parasympathetic nervous system, thereby promoting the production of bile, saliva, and sweat. Traditionally, American Indians used the root as a poultice for swellings, sores, wounds, bruises, ulcers, and even to reduce freckles. In homeopathic literature Iris versicolor is clinically indicated in psoriasis.
Due to lack of clinical evidence evaluating the effectiveness of individualized homoeopathic medicine using Kent’s Repertory and insufficient evidence on therapeutic efficacy of Iris versicolor in psoriasis, this study aims to assess the effectiveness of Iris versicolor and individualised homoeopathic medicine selected using Kent’s Repertory in management of plaque psoriasis.
NULL HYPOTHESIS : There may not be a significant difference between the effectiveness of Iris versicolor and Individualized Homoeopathic Medicine selected using Kent’s Repertory in management of plaque psoriasis.
ALTERNATIVE HYPOTHESIS : There may be a significant difference between the effectiveness of Iris versicolor and Individualized Homoeopathic Medicine selected using Kent’s Repertory in management of plaque psoriasis.
 
Close